Theravance’s Telavancin Prompts Renal Concerns, But No Questions From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.
You may also be interested in...
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits
J&J/Basilea’s Ceftobiprole Gets Another Setback
FDA stops the investigational antibiotic’s six-month review clock for additional clinical site audits, data integrity review.